WESTON, Fla., Sept. 14, 2021 /PRNewswire/ -- Cantex Pharmaceuticals, Inc. ("Cantex") today announced that it has sold 6.5 million shares of Chimerix, Inc. in brokerage transactions at a price of $5.75 per share, less brokerage commissions and fees.

About Cantex Pharmaceuticals
Cantex Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on the transformation of known drugs into innovative products with blockbuster potential. Cantex is currently developing novel cancer treatments. Cantex's pipeline consists of three product candidates in Phase 2 and Phase 3 development for diseases with significant unmet medical needs: Azeliragon for life-threatening and disabling complications of cancer, Dicopp^® for hematologic malignancies, and DSTAT, licensed to Chimerix, Inc., as a first-line therapy of acute myeloid leukemia. For more information, please visit www.cantex.com.

More on S For Story

• GSP International Airport integrates a new enterprise operations platform offered by Aerosimple
• Author Katy Duncan releases the first in a series of young adult paranormal novels, Soul Taken
• Down & Out Books Signs Susan Wingate's Latest Domestic Thriller
• Electric Violinist, James Teal Recognized With $5,000 City Artists Corps Grant From NY Foundation For The Arts & The NYC Dept Of Cultural Affairs
• Slide Guitarist Co-Writes Song about a Broken Voice

Cantex Contacts
Investors:
Stephen G. Marcus, M.D.
(954) 315-3660
[email protected]

or

Media:
Jason Rando
Tiberend Strategic Advisors
(917) 930-6346
[email protected]

SOURCE Cantex Pharmaceuticals, Inc.

---

Show All News | Report Violation